TB-500 side effects
TB-500 side effects — the loading-phase flu-like response, blood pressure considerations, and how the long half-life shapes the safety profile.
Updated May 7, 2026 · 4 min read
TB-500's side-effect profile overlaps with BPC-157's, but with a few category-specific quirks driven by the long tissue half-life and the loading-phase pattern. Most reports are mild; the cancer-related caution is the same as for BPC-157.
The loading-phase response
The most distinctive TB-500-specific side effect is a flu-like feeling that can appear 24–48 hours after a loading-phase dose:
- Mild fatigue
- Body aches
- Slight fever feeling (but rarely actual fever)
- Mild headache
This is most pronounced in the first 1–2 weeks of loading and usually fades as the body adapts. Splitting the loading dose (half-dose twice as often) often dampens it.
If actual fever, severe symptoms, or spreading reaction occurs — that's not the typical loading response. Stop and seek medical attention.
Common reports
| Effect | Frequency | Onset | What to do |
|---|---|---|---|
| Flu-like 24–48h post-dose | Common in loading | 1–2 days | Pre-hydrate; consider split dose; usually fades |
| Lethargy | Common | Within hours | Time loading doses for off-days |
| Mild blood-pressure changes | Occasional | Variable | Monitor; reduce dose |
| Headaches | Occasional | Within 24h | Hydrate; reduce dose if persistent |
| Injection-site redness | Common | Immediate | Rotate sites |
| Mild lightheadedness | Occasional | Within hours | Hydrate |
Blood pressure considerations
TB-500's effects on circulation can produce mild blood pressure shifts. Most users don't notice. A few:
- Report transient drops after dose (lightheadedness on standing)
- Report mild elevations during loading
If you have baseline hypertension, hypotension, or take BP medication: monitor cuff readings during your first loading cycle and discuss with your clinician.
Long-half-life implications
TB-500 stays in tissue for days. That has practical consequences for side-effect management:
- You can't quickly reverse a side effect by stopping. Whatever's in tissue is there for a while.
- Cycling matters. If side effects are accumulating, an extended off-period (4–8 weeks minimum) is necessary, not just skipping a few days.
- Re-introduction tolerance is unclear. Coming back after a long off-period sometimes brings the loading-phase response back.
This is the operational difference vs. BPC-157, which clears in hours. With BPC-157, you can dial up and down quickly. With TB-500, you commit to the cycle and adjust slowly.
The angiogenesis / cancer question
The same theoretical concern as BPC-157 applies, possibly more so:
- TB-500 promotes cell migration including endothelial migration
- It upregulates pathways involved in angiogenesis
- It supports tissue regeneration broadly
The pre-clinical record (in cardiac repair, corneal healing, neural recovery) is positive — but most of that record is on the parent thymosin beta-4 protein, not the TB-500 fragment specifically. Long-term human cancer-incidence data does not exist.
The right posture:
- Active or recent cancer: don't use TB-500
- Family history of cancer: discuss with clinician
- History of melanoma specifically: the actin-binding mechanism intersects with melanoma research in concerning ways — extra caution warranted
- No cancer history, normal screening: the risk is theoretical; proceed informed
Vendor-related issues
Like BPC-157, much of what gets attributed to "TB-500 side effects" is actually:
- Endotoxin contamination — particularly common in research-chem TB-500 due to manufacturing complexity. Produces strong flu-like response disproportionate to dose.
- TB-500 fragment vs full thymosin beta-4 mislabeling — the two are sold in similar vials at very different prices
- Concentration error — overdose is the most common cause of severe loading-phase response
If your loading-phase response is dramatically out of proportion to dose, suspect the vial before suspecting the protocol. See vendor quality checks.
When to stop
Standard stop signals:
| Symptom | Action |
|---|---|
| Persistent flu-like response past week 2 | Reduce loading dose; re-evaluate vendor |
| Spreading rash or systemic allergic reaction | Stop immediately; seek medical attention |
| Sudden severe headache or vision change | Stop immediately; seek medical attention |
| Cardiac symptoms — palpitations, chest pain | Stop immediately; seek medical attention |
| Unusual bleeding or unexplained bruising | Stop immediately; seek medical attention |
| New lump or skin lesion | Stop and consult a dermatologist |
Drug interaction caveats
- Anticoagulants: TB-500's vascular effects may interact; not well-studied
- Active chemotherapy: absolute contraindication
- Immunosuppressants: discuss with clinician
Pregnancy and lactation
Not studied. Don't.
A reasonable starting safety protocol
If you're going to run TB-500:
- Start at the low end of loading. 2 mg twice weekly for first 2 weeks before scaling.
- Pre-hydrate before each loading dose.
- Time loading doses for off-days in case of flu-like response.
- Track BP through the first loading cycle.
- Vendor with COA only. TB-500 quality varies widely.
- Don't stack with BPC-157 on the first cycle — establish your TB-500 baseline first.
- Annual labs. CBC, basic metabolic, lipid panel.